Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922623 | 1.00 | POLB (0.40) | POLBCYP2C19SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL1010909 | 0.92 | CYP2C19 (0.38) | POLBCYP2C19SMN1; SMN2ACE | |
| SCHEMBL1922216 | 0.84 | POLB (0.42) | POLBSMN1; SMN2ACEMEN1KMT2A | |
| SCHEMBL1066125 | 0.84 | POLB (0.42) | POLBSMN1; SMN2ACEMEN1KMT2A | |
| SCHEMBL1923117 | 0.83 | ACE (0.42) | POLBCYP2C19SMN1; SMN2ACEMEN1 | |
| SCHEMBL1009458 | 0.83 | ACE (0.42) | POLBCYP2C19SMN1; SMN2ACEMEN1 | |
| SCHEMBL1010222 | 0.83 | TBXA2R (0.38) | ENPP1 | |
| SCHEMBL2789735 | 0.81 | PTGDR2 (0.53) | POLBCYP2C19SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL3443645 | 0.81 | PTGDR2 (0.53) | POLBCYP2C19SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL1010021 | 0.80 | RAB9A (0.42) | POLBACEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960393-B2 | Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 | ACTIMIS PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| EP-1633726-B1 | PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 | ACTIMIS PHARMACEUTICALS INC (US) | 2011-01-05 | — | — | EP | disclosed |